{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:47:31Z","timestamp":1785822451344,"version":"3.56.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Fluoropyrimidines are widely used in the treatment of multiple neoplasms, but their use is limited by the risk of severe toxicity in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. Current clinical guidelines recommend\n                      <jats:italic>DPYD<\/jats:italic>\n                      genotyping as pre-treatment screening for a limited number of common variants; however, this approach fails to identify all patients at risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Description<\/jats:title>\n                    <jats:p>\n                      We describe the case of a man with resected gastric adenocarcinoma, wild type for the\n                      <jats:italic>DPYD<\/jats:italic>\n                      recommended variants, who developed early-onset, life-threatening toxicity shortly after few days of adjuvant capecitabine-based chemotherapy at full dose. The clinical course was characterized by grade 4 gastrointestinal toxicity complicated by septic shock, which required prolonged hospitalization and led to the definitive discontinuation of chemotherapy. Extensive Next-Generation Sequencing (NGS) revealed a heterozygous deletion spanning from exons 5 to 20 (for a total of about 500\u00a0Kb) of the\n                      <jats:italic>DPYD<\/jats:italic>\n                      gene. The presence of this deletion was validated using Single Nucleotide Polymorphism (SNP) Array. Functional analysis, based on assessment of DPD activity in peripheral blood mononuclear cells (PBMCs) and plasma concentrations of uracil and dihydrouracil, confirmed the impaired DPD function.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This case highlights the limitations of routine\n                      <jats:italic>DPYD<\/jats:italic>\n                      genotyping strategies and emphasizes the clinical relevance of rare structural variants as an underestimated cause of severe fluoropyrimidine-related toxicity. The use of comprehensive NGS approach in pharmacogenetic diagnostics should be considered as a step forward in the identification of patients at risk of fluoropyrimidines-related toxicity particularly in the context of adjuvant therapy, where it is essential to strike a balance between therapeutic benefits and unacceptable toxicity.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1866621","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:39:08Z","timestamp":1785821948000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification of a large DPYD gene deletion undetected by standard genotyping in a patient with severe capecitabine-related toxicity: a case report"],"prefix":"10.3389","volume":"17","author":[{"given":"Marco Donatello","family":"Delcuratolo","sequence":"first","affiliation":[{"name":"Oncology Unit, Fondazione IRCCS Casa Sollievo della Sofferenza","place":["San Giovanni Rotondo (FG), Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Rodriquenz","sequence":"additional","affiliation":[{"name":"Oncology Unit, Fondazione IRCCS Casa Sollievo della Sofferenza","place":["San Giovanni Rotondo (FG), Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Morelli","sequence":"additional","affiliation":[{"name":"Oncology Unit, Fondazione IRCCS Casa Sollievo della Sofferenza","place":["San Giovanni Rotondo (FG), Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana Pia","family":"Latiano","sequence":"additional","affiliation":[{"name":"Oncology Unit, Fondazione IRCCS Casa Sollievo della Sofferenza","place":["San Giovanni Rotondo (FG), Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Anna","family":"Muscarella","sequence":"additional","affiliation":[{"name":"Lung Cancer Research Unit, Fondazione IRCCS Casa Sollievo della Sofferenza","place":["San Giovanni Rotondo (FG), Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Caporilli","sequence":"additional","affiliation":[{"name":"Life Sciences and Diagnostic Group, Agilent Technologies Italia S.p.A. Cernusco sul Naviglio","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Pasqualini","sequence":"additional","affiliation":[{"name":"Life Sciences and Diagnostic Group, Agilent Technologies Italia S.p.A. Cernusco sul Naviglio","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"De Santis","sequence":"additional","affiliation":[{"name":"Hematopathology Unit, Institute for Stem Cell Biology, Regenerative Medicine and Innovative Therapeutics (ISBReMIT), Fondazione IRCCS Casa Sollievo della Sofferenza","place":["San Giovanni Rotondo (FG), Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Giambra","sequence":"additional","affiliation":[{"name":"Hematopathology Unit, Institute for Stem Cell Biology, Regenerative Medicine and Innovative Therapeutics (ISBReMIT), Fondazione IRCCS Casa Sollievo della Sofferenza","place":["San Giovanni Rotondo (FG), Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rinaldi","sequence":"additional","affiliation":[{"name":"Medicina Trasfusionale e Laboratorio Analisi, Fondazione IRCCS Casa Sollievo Della Sofferenza","place":["San Giovanni Rotondo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Ciavarella","sequence":"additional","affiliation":[{"name":"Medicina Trasfusionale e Laboratorio Analisi, Fondazione IRCCS Casa Sollievo Della Sofferenza","place":["San Giovanni Rotondo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Floris","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Murru","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Binaghi Hospital, ASL Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Mascia","sequence":"additional","affiliation":[{"name":"Unit of Oncology and Molecular Pathology, Department of Biomedical Sciences, University of Cagliari","place":["Cagliari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"De Mattia","sequence":"additional","affiliation":[{"name":"Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS","place":["Aviano (PN), Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Canil","sequence":"additional","affiliation":[{"name":"Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS","place":["Aviano (PN), Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fania","sequence":"additional","affiliation":[{"name":"Medicina Trasfusionale e Laboratorio Analisi, Fondazione IRCCS Casa Sollievo Della Sofferenza","place":["San Giovanni Rotondo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Pop","sequence":"additional","affiliation":[{"name":"Amsterdam UMC, Vrije Universiteit Amsterdam, Laboratory Genetic Metabolic Diseases","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Carella","sequence":"additional","affiliation":[{"name":"Medical Genetics Unit, Fondazione IRCCS Casa Sollievo della Sofferenza","place":["San Giovanni Rotondo (FG), Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"van Kuilenburg","sequence":"additional","affiliation":[{"name":"Amsterdam UMC, Vrije Universiteit Amsterdam, Laboratory Genetic Metabolic Diseases","place":["Amsterdam, Netherlands"]},{"name":"Cancer Center Amsterdam","place":["Amsterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Cecchin","sequence":"additional","affiliation":[{"name":"Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS","place":["Aviano (PN), Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Miscio","sequence":"additional","affiliation":[{"name":"Medicina Trasfusionale e Laboratorio Analisi, Fondazione IRCCS Casa Sollievo Della Sofferenza","place":["San Giovanni Rotondo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"B1","unstructured":"Raccomandazioni per analisi farmacogenetiche\n          \n          \n          2024"},{"key":"B2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1199462","DOI":"10.3389\/fphar.2023.1199462","article-title":"Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: lessons learned on the path to implementation","volume":"14","author":"Bignucolo","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1559325820951367","DOI":"10.1177\/1559325820951367","article-title":"Comparison of 4 screening methods for detecting fluoropyrimidine toxicity risk: identification of the most effective, cost-efficient method to save lives","volume":"18","author":"Capitain","year":"2020","journal-title":"Dose Response"},{"key":"B5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1515\/cclm-2025-0949","article-title":"Impact of renal and hepatic function on dihydropyrimidine dehydrogenase phenotype assessed by enzyme activity in peripheral blood mononuclear cells and uracilemia","volume":"64","author":"Contu","year":"2025","journal-title":"Clin. Chem. Lab. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1459565","DOI":"10.3389\/fphar.2024.1459565","article-title":"Case report: a case of severe capecitabine toxicity due to confirmed in trans compound heterozygosity of a common and rare DPYD variant","volume":"15","author":"de Haar-Holleman","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"113644","DOI":"10.1016\/j.biopha.2022.113644","article-title":"Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk","volume":"154","author":"De Mattia","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.7150\/ijbs.97686","article-title":"Clinical implementation of rare and novel DPYD variants for personalizing fluoropyrimidine treatment: challenges and opportunities","volume":"20","author":"De Mattia","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1038\/s41388-025-03587-7","article-title":"Integration of germline pharmacogenomic burden to predict fluoropyrimidine-related toxicity - a secondary analysis of the PREPARE trial","volume":"44","author":"De Mattia","year":"2025","journal-title":"Oncogene"},{"key":"B10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2165\/00003088-198916040-00002","article-title":"Clinical pharmacology of 5-fluorouracil","volume":"16","author":"Diasio","year":"1989","journal-title":"Clin. Pharmacokinet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejca.2022.11.028","article-title":"Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency","volume":"181","author":"Etienne-Grimaldi","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"B12","unstructured":"EMA recommendations on DPYD testing prior to treatment with fluorouracil, capecitabine, tegafur and flucytosine\n          \n          \n          2020"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.2147\/CMAR.S174470","article-title":"Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene","volume":"10","author":"Garc\u00eda-Gonz\u00e1lez","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/clinchem\/hvae181","article-title":"Integrating pharmacogenomics into the broader construct of genomic medicine: efforts by the ClinGen pharmacogenomics working group (PGxWG)","volume":"71","author":"Gong","year":"2025","journal-title":"Clin. Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","volume":"19","author":"Henricks","year":"","journal-title":"Lancet Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/ijc.31065","article-title":"Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency","volume":"142","author":"Henricks","year":"","journal-title":"Int. J. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/psp4.12474","article-title":"Pharmacokinetics of capecitabine and four metabolites in a heterogeneous population of cancer patients: a comprehensive analysis","volume":"8","author":"Jacobs","year":"2019","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/cpt.2069","article-title":"Individualized dosing of fluoropyrimidine-based chemotherapy to prevent severe fluoropyrimidine-related toxicity: what are the options?","volume":"109","author":"Knikman","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/cpt.3100","article-title":"A nomogram to predict severe toxicity in DPYD wild-type patients treated with Capecitabine-Based anticancer regimens","volume":"115","author":"Knikman","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"115483","DOI":"10.1016\/j.ejca.2025.115483","article-title":"Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study","volume":"224","author":"Knikman","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41397-023-00322-x","article-title":"Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity","volume":"24","author":"Larrue","year":"2024","journal-title":"Pharmacogenomics J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/s41416-023-02517-2","article-title":"Dihydropyrimidine dehydrogenase gene variants for predicting grade 4\u20135 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis","volume":"130","author":"Le Teuff","year":"2024","journal-title":"Br. J. Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"00067","DOI":"10.1200\/PO.20.00067","article-title":"Severe capecitabine toxicity associated with a rare DPYD variant identified through whole-genome sequencing","volume":"4","author":"Ly","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12920-024-01846-2","article-title":"A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report","volume":"17","author":"Malekkou","year":"2024","journal-title":"BMC Med. Genomics"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","article-title":"Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data","volume":"16","author":"Meulendijks","year":"2015","journal-title":"Lancet Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jmoldx.2024.05.015","article-title":"DPYD genotyping recommendations: a joint consensus recommendation of the association for molecular pathology, American college of medical genetics and genomics, clinical pharmacogenetics implementation consortium, college of American pathologists, Dutch pharmacogenetics working group of the royal Dutch pharmacists association, european society for pharmacogenomics and personalized therapy, pharmacogenomics knowledgebase, and pharmacogene variation consortium","volume":"26","author":"Pratt","year":"2024","journal-title":"J. Mol. Diagn"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1200\/JCO-25-02896","article-title":"Dear doctor: we still have no idea of what dose of capecitabine you should prescribe","volume":"44","author":"Ratain","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00280-021-04236-y","article-title":"Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population","volume":"87","author":"Saarenheimo","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3389\/fonc.2018.00279","article-title":"A novel DPYD variant associated with severe toxicity of fluoropyrimidines: role of pre-emptive DPYD genotype screening","volume":"8","author":"Tong","year":"2018","journal-title":"Front. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/ijc.10599","article-title":"Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1G>A mutation","volume":"101","author":"van Kuilenburg","year":"2002","journal-title":"Int. J. Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00439-009-0653-6","article-title":"Analysis of severely affected patients with dihydropyrimidine dehydrogenase deficiency reveals large intragenic rearrangements of DPYD and a de novo interstitial deletion del(1)(p13.3p21.3)","volume":"125","author":"van Kuilenburg","year":"2009","journal-title":"Hum. Genet."},{"key":"B34","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00439-010-0879-3","article-title":"Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity","volume":"128","author":"van Kuilenburg","year":"2010","journal-title":"Hum. Genet."},{"key":"B35","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.bbadis.2016.12.010","article-title":"Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing","volume":"1863","author":"van Kuilenburg","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/curroncol30010051","article-title":"DPYD exon 4 deletion associated with fluoropyrimidine toxicity and importance of copy number variation","volume":"30","author":"Wigle","year":"2023","journal-title":"Curr. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1866621\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:39:10Z","timestamp":1785821950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1866621\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":35,"alternative-id":["10.3389\/fphar.2026.1866621"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1866621","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"article-number":"1866621"}}